New Long-Acting Insulin Shown to be Better

1917

There was an outcry from insulin users when Novo Nordisk and Eli Lilly decided to withdraw animal-derived basal insulins from the market and replace them with biosynthetic NPH and Ultralente, which many consumers consider inferior. These same critics are hoping that a new generation of basal insulins such as HOE901, Basulin and Lantus will prove to be more effective.

In a multinational study, the effect of HOE901 on the blood glucose control of 333 type 1 patients was compared to that of NPH insulin over a period of four weeks. It was found that both fasting plasma and self-monitored blood glucose levels were much lower with HOE901. HbA1c levels and the frequency of nighttime lows were also significantly lower with HOE901 versus NPH.

Comments

comments

This post authored by
Diabetes Health Medical Disclaimer
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.